| 
|  |  |  
| Species: | Dog |  
| Strain/breeder: | Beagle / Marshall |  
| Sex: | Male (8A), female (8B) |  
| Age: | 12-14 Months |  
| Study type: | Oral, 4 weeks treatment |  
| Treatment: | Anticancer compound, high dose |  
| Animal status: | Scheduled sacrifice: 8A: after 4 weeks treatment
8B: after an additional 6-week recovery period |  
| Clinical findings: | Salivation, vomiting, body weight loss, anemia, leukopenia, increased liver enzymes |  
| Organ(s): | Liver |  
| Macroscopic finding(s):
 | None |  
| Staining: | H&E |  | 
|  |  
|  Fig. 1 (130k)
 
 
  Fig. 2 (132k)
 
 
 |  |